Full Text View
Tabular View
Study Results
Related Studies
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
This study has been completed.
Study NCT00224133   Information provided by Watson Pharmaceuticals

First Received on September 14, 2005.   Last Updated on April 6, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Benign Prostatic Hyperplasia
Additional conditions recognized in this trial
Hyperplasia
Prostatic Hyperplasia
More general conditions related to this trial
Genital Diseases, Male
Pathologic Processes
Prostatic Diseases
Interventions listed in this trial
Silodosin
Sponsors listed in this trial
Watson Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services